Literature DB >> 8217588

Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.

A J Swerdlow1, A J Douglas, G Vaughan Hudson, B Vaughan Hudson, K A MacLennan.   

Abstract

The risks of second primary cancer were analysed in 2846 patients with Hodgkin's disease treated within the British National Lymphoma Investigation during 1970-87. The relative risk (RR) of leukaemia was significantly greater in women (RR = 30.1; 95% confidence limits (CL) 13.0-59.5) than in men (RR = 10.9; 95% CL 4.7-21.5), and showed a significant trend of greater risk with younger age at first treatment (P < 0.001). The relative risk of solid cancers was similar between the sexes, but again significantly greater at young than at older ages of first treatment (P < 0.01). Non-Hodgkin's lymphoma relative risks, although not related to sex or age, were significantly related to histology of the original Hodgkin's disease, and were greatest after lymphocyte predominant Hodgkin's disease (RR = 55.6; 95% CL 18.0-129.7). The relative risk of second cancers did not vary significantly according to whether or not splenectomy had been performed. Leukaemia risk was non-significantly greater after splenectomy than with no splenectomy, which accorded with previous evidence of a modest increased risk associated with this operation. If the greater relative risk of solid second cancers after treatment at young than at older ages persists with longer follow-up, the incidence rates of these second primaries in patients treated young for Hodgkin's disease will become very substantial as they age. This emphasises the need to maintain long-term follow-up surveillance of young Hodgkin's disease patients apparently cured of their disease, and to continue to develop new less carcinogenic treatment regimens.

Entities:  

Mesh:

Year:  1993        PMID: 8217588      PMCID: PMC1968752          DOI: 10.1038/bjc.1993.470

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Lymphocyte predominant Hodgkin's disease nodular subtype with coexistent "large cell lymphoma". Histological progression or composite malignancy?

Authors:  J T Sundeen; J Cossman; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1988-08       Impact factor: 6.394

2.  Risk of second cancers after treatment for Hodgkin's disease.

Authors:  M A Tucker; C N Coleman; R S Cox; A Varghese; S A Rosenberg
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

3.  Leukemia following Hodgkin's disease.

Authors:  J M Kaldor; N E Day; E A Clarke; F E Van Leeuwen; M Henry-Amar; M V Fiorentino; J Bell; D Pedersen; P Band; D Assouline
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

4.  Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation.

Authors:  M H Bennett; K A MacLennan; G Vaughan Hudson; B Vaughan Hudson
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

5.  Nodular paragranuloma can transform into high-grade malignant lymphoma of B type.

Authors:  M L Hansmann; H Stein; C Fellbaum; P K Hui; M R Parwaresch; K Lennert
Journal:  Hum Pathol       Date:  1989-12       Impact factor: 3.466

6.  Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease.

Authors:  F E van Leeuwen; R Somers; B G Taal; P van Heerde; B Coster; T Dozeman; S J Huisman; A A Hart
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

7.  Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

Authors:  J Pedersen-Bjergaard; L Specht; S O Larsen; J Ersbøll; J Struck; M M Hansen; H H Hansen; N I Nissen
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

Review 8.  Second malignancies and Hodgkin's disease--the Royal Marsden Hospital experience.

Authors:  M Colman; D F Easton; A Horwich; M J Peckham
Journal:  Radiother Oncol       Date:  1988-03       Impact factor: 6.280

Review 9.  Solid cancer risk after treatment of Hodgkin's disease.

Authors:  J F Boivin; K O'Brien
Journal:  Cancer       Date:  1988-06-15       Impact factor: 6.860

10.  Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease.

Authors:  J W van der Velden; W L van Putten; V F Guinee; R Pfeiffer; F E van Leeuwen; E A van der Linden; I Vardomskaya; W Lane; M Durand; C Lagarde
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

View more
  7 in total

Review 1.  Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  A J Swerdlow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

2.  Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.

Authors:  A J Swerdlow; J A Barber; A Horwich; D Cunningham; S Milan; R Z Omar
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Late effects of treatment for early-stage Hodgkin's disease.

Authors:  J D Brierley; A J Rathmell; M K Gospodarowicz; S B Sutcliffe; A Munro; R Tsang; M Pintilie
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.

Authors:  C N Harrison; W Gregory; G V Hudson; S Devereux; A H Goldstone; B Hancock; D Winfield; A K MacMillan; P Hoskin; A C Newland; D Milligan; D C Linch
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

5.  Racial/Ethnic Disparities on the Risk of Second Malignant Neoplasm Among Hodgkin Lymphoma Survivors.

Authors:  Han Xiao; Jianghua He; Simin Liang; Duo Cai; Qiao Zhou; Lanxiang Liu; Xinyu Yan; Jianxiang Chi; Qing Xiao; Li Wang
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

6.  DNA topoisomerases participate in fragility of the oncogene RET.

Authors:  Laura W Dillon; Levi C T Pierce; Christine E Lehman; Yuri E Nikiforov; Yuh-Hwa Wang
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

7.  Second primary neoplasms in thyroid cancer patients.

Authors:  K Ishikawa; S Noguchi; K Tanaka; A Fukuda; T Hirohata
Journal:  Jpn J Cancer Res       Date:  1996-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.